E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2374-4677
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer ; volume:4 ; number:1 ; day:11 ; month:1 ; year:2018 ; pages:1-5 ; date:12.2018
npj Breast cancer ; 4, Heft 1 (11.1.2018), 1-5, 12.2018
- Schlagwort
-
Krebs
Onkologie
- Urheber
-
Yeruva, Sri Lakshmi Hyndavi
- Beteiligte Personen und Organisationen
-
Zhao, Fengmin
Miller, Kathy D.
Tevaarwerk, Amye J.
Wagner, Lynne I.
Gray, Robert J.
Sparano, Joseph A.
Connolly, Roisin M.
SpringerLink (Online service)
- DOI
-
10.1038/s41523-017-0053-3
- URN
-
urn:nbn:de:1111-201803032115
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:54 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Yeruva, Sri Lakshmi Hyndavi
- Zhao, Fengmin
- Miller, Kathy D.
- Tevaarwerk, Amye J.
- Wagner, Lynne I.
- Gray, Robert J.
- Sparano, Joseph A.
- Connolly, Roisin M.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer
Constitutively active androgen receptor supports the metastatic phenotype of endocrine-resistant hormone receptor-positive breast cancer
Cost-Effectiveness Analysis of Fulvestrant 500 mg in Endocrine Therapy-Naïve Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer in the UK
SABCS 2017: lifestyle factors, hormone receptor-positive advanced disease, liquid biopsies, and prognosis
CDK4/6 Inhibitors—Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer
Factors associated with initiation and continuation of endocrine therapy in women with hormone receptor-positive breast cancer
Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy
Rat Models of Hormone Receptor-Positive Breast Cancer
Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trials
Clinical efficacy of combined goserelin and anastrozole in neoadjuvant endocrine therapy for premenopausal women with hormone receptor-positive breast cancer
Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer
Constitutively active androgen receptor supports the metastatic phenotype of endocrine-resistant hormone receptor-positive breast cancer
Cost-Effectiveness Analysis of Fulvestrant 500 mg in Endocrine Therapy-Naïve Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer in the UK
SABCS 2017: lifestyle factors, hormone receptor-positive advanced disease, liquid biopsies, and prognosis
CDK4/6 Inhibitors—Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer
Factors associated with initiation and continuation of endocrine therapy in women with hormone receptor-positive breast cancer
Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy
Rat Models of Hormone Receptor-Positive Breast Cancer
Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trials
Clinical efficacy of combined goserelin and anastrozole in neoadjuvant endocrine therapy for premenopausal women with hormone receptor-positive breast cancer
Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer
Constitutively active androgen receptor supports the metastatic phenotype of endocrine-resistant hormone receptor-positive breast cancer
Cost-Effectiveness Analysis of Fulvestrant 500 mg in Endocrine Therapy-Naïve Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer in the UK
SABCS 2017: lifestyle factors, hormone receptor-positive advanced disease, liquid biopsies, and prognosis
CDK4/6 Inhibitors—Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer
Factors associated with initiation and continuation of endocrine therapy in women with hormone receptor-positive breast cancer
Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy
Rat Models of Hormone Receptor-Positive Breast Cancer
Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trials